In breast cancer cell line T-47D, which is ERα- and AR-positive, treatment with the aromatase inhibitor exemestane was shown to result in increased HSD17B2 expression, a change which was associated with increased DHT expression. The gene discussed is CYP19A1; the disease is breast carcinoma.